Items where authors include "Touraine, P.A."

Article

Tschaidse, L., Reisch, N. orcid.org/0000-0002-7469-6069, Arlt, W. orcid.org/0000-0001-5106-9719 et al. (15 more authors) (2023) Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia. European Journal of Endocrinology, 188 (1). lvac006. pp. 109-117. ISSN 0804-4643

Merke, D.P., Mallappa, A., Arlt, W. et al. (14 more authors) (2020) OR25-02 A phase 3 study of a modified-release hydrocortisone in the treatment of congenital adrenal hyperplasia. Journal of the Endocrine Society, 4 (Supplement_1).

Proceedings Paper

Lawrence, N.R. orcid.org/0000-0002-7560-0268, Krone, N.P., Dawson, J.F. et al. (15 more authors) (2024) 6437 Analysis of 17-OH-progesterone (17OHP) and androstenedione (A4) profiles to rationalise biochemical monitoring of CAH patients. In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society .

Ross, R.J.M., Merke, D.P., Mallappa, A. et al. (14 more authors) (2024) 7061 Incidence of adrenal crisis in Congenital Adrenal Hyperplasia (CAH) patients during a prospective monitored long-term study of modified-release hydrocortisone (MRHC) capsules, (Efmody). In: Journal of the Endocrine Society. ENDO 2024 Abstracts Annual Meeting of the Endocrine Society, 01-04 Jun 2024, Boston, USA. The Endocrine Society .